Full Press Release Details
Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
Full Year 2021 Product Sales were approximately $40.1 million, including core non-COVID-19 sales growth of approximately 13% from 2020.
Cumulative CytoSorb treatments surpassed 162,000.
JUNCTION, NJ - January 18, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening
conditions in the intensive care unit and cardiac surgery using blood purification, issues a stockholder letter from its Chief Executive
Officer, Dr. Phillip Chan, and announces preliminary unaudited fourth quarter 2021 and full year 2021 results ahead of filing its Form
Unaudited Full Year 2021 Results
Unaudited Q4 2021 Results
Company expects to report fully-audited financial results for Q4 2021 and full year 2021 and its 2022 outlook on Tuesday, March 8, 2022,
with a conference call held at 4:30PM ET. Further details for the earnings call will be provided at a later date.
2022: Focus and Disciplined Execution
Stockholders and Friends,
an exceptionally strong year in 2020 where CytoSorb sales rose 73% and roughly a quarter of our sales were COVID-19 related, we had a
good year in 2021 with total revenue of $43.2 million and product sales of $40.1 million, both slightly ahead of our record results in
2020, despite headwinds from the COVID-19 pandemic. Importantly, our business in Germany rebounded in the fourth quarter, with sales
increasing by a healthy 45% compared to the third quarter of 2021. For the year, Germany sales were up 4% from strong 2020 sales in the
country. We also grew core (non-COVID-19) sales by a respectable 13% year-over-year. Over the past five years, our compounded annual
growth rate has been a strong 37% and we continue to generate robust product gross margins of at least 80%. Finally, we have a solid
cash position of nearly $54 million at year-end and no near-term need or intent to raise capital. In the first quarter of 2022, we plan
to renew our $15 million term loan agreement with Bridge Bank, ensuring continued financial flexibility.
achieved these results in a period of great uncertainty, where COVID continues to impact businesses in every industry around the world.
We have already discussed at great length the complicated dynamics related to the pandemic and our business, with benefits related to
COVID-19 usage - generating an estimated $6.3 million in 2021 CytoSorb sales - and the halo effect on usage in other critical care therapy
applications. However, the pandemic created two headwinds in 2021.
the tidal wave of new, highly contagious Delta and Omicron infections may in fact be heralding the beginning of the end of COVID, as
the unvaccinated masses unfortunately get naturally immunized the hard way, and vaccinated people get naturally boosted with mild disease,
inching us closer to the elusive "herd immunity." If this happens, COVID and its variants may still be with us for years
to come, but as a milder seasonal respiratory illness like influenza.
we wait for COVID to run its course, we have been actively implementing our core business strategy emphasizing Focus and Disciplined
Execution. During 2021, we strategically used our substantial cash position to strengthen the organization from all aspects.
| We leveraged our two FDA Breakthrough Device Designations to rapidly begin the pivotal U.S. randomized, controlled trials: STAR-T and STAR-D. These studies are designed to support CytoSorbents' first U.S. FDA marketing approval of DrugSorb -ATR to reduce bleeding risk in patients on antithrombotic medications (aka "blood thinners") undergoing cardiothoracic surgery and to open up access to the U.S. market. To date, we are pleased with the pace of enrollment of the STAR-T trial and continue to forecast enrollment completion of the study in 2022. We also expect the STAR-D trial to enroll its first patient shortly, trailing STAR-T by only a few months. | ||
| We made significant investments in both people and infrastructure across the Company, particularly optimizing and more closely aligning our international sales, marketing, and medical affairs teams to ensure synergy and focus on key critical care and cardiac surgery applications that have the potential to drive rapid growth and profitability. | ||
| We expanded our clinical team and are investing in important Company-sponsored clinical studies and registries to generate data that are intended to drive faster adoption and sales of CytoSorb. These include, for example, the PROCYSS refractory septic shock randomized controlled trial, the Hep-on-Fire trial in alcoholic liver disease, the U.S. multicenter CTC ( C ytoSorb T herapy in C OVID-19) registry and recent publication highlighting the high 73% survival in the most critically ill COVID-19 patients on CytoSorb and extracorporeal membrane oxygenation (ECMO), and the international COSMOS ( C yt OS orb Treat M ent of Critically Ill Patient S ) critical care registry. |
| We are making excellent progress in building out and scaling up our new manufacturing facility and the Company's expected future headquarters in Princeton, New Jersey that | ||
| is expected to expand our production capacity from what is currently $80 million, to $350-400 million in sales, and to drive our already outstanding product gross margins even higher. This facility is on track to be completed and validated by this summer, and to begin manufacturing product in the second half of this year. | ||
| As long as the pandemic continues, we will work to help critically ill COVID-19 patients with CytoSorb. To date, CytoSorb has been used to treat more than an estimated 7,600 COVID-19 patients worldwide. Our continued focus and investments on making the published data on this usage widely available has also helped to accelerate adoption of CytoSorb for core (non-COVID-19) applications in many countries around the world. As more data are released from the CTC registry this year, we expect this trend will continue. The pandemic has been a valuable global marketing opportunity to elevate the CytoSorb brand and to emphasize to physicians how CytoSorb is easily implemented and used to treat many of the most common and complex complications in the ICU, such as shock and lung failure, whether or not related to COVID-19. |
U.S. STAR-T and STAR-D Pivotal Studies: The Potential Tipping Point of Substantial Growth
DrugSorb -ATR antithrombotic removal system can efficiently remove antithrombotic drugs, often called "blood thinners,"
such as apixaban (Eliquis ; Pfizer, Bristol Myers Squibb), rivaroxaban (Xarelto , Janssen and Bayer), and ticagrelor (Brilinta ;
Astra Zeneca). DrugSorb-ATR is being evaluated in the U.S. under two FDA Breakthrough Device Designations (BDD) for the potential to
remove these agents and reduce perioperative bleeding in the U.S.-based randomized, controlled pivotal trials: STAR-T and STAR-D (Safe
and Timely Antithrombotic Removal of Ticagrelor [i.e. Brilinta ], and Direct Oral Anticoagulants
[DOACs; e.g. Eliquis and Xarelto ]), respectively. Both multicenter trials are designed to independently support U.S. FDA marketing
approval and are relatively modest in size, with each enrolling up to 120 patients. As mentioned previously, we are pleased with the
pace of enrollment of the STAR-T trial since the first patient was enrolled last October, even with the holidays, COVID surge, and nationwide
hospital staffing shortages, and continue to project enrollment completion this year, assuming a return to relatively normal clinical
trial activity at participating centers. We expect STAR-D to follow quickly, with first patient enrollment expected shortly. We plan
to submit rapidly for U.S. FDA marketing approval after study completion.
a reminder, these blockbuster medications are prescribed to millions of patients around the world to "thin the blood" and
prevent blood clots from forming that could lead to a heart attack, stroke, or other ischemic event. Currently, the only recommended
intervention to reverse the anti-clotting effect of these drugs is to allow the drug to be eliminated naturally over time. When patients
on these medications need to undergo urgent or emergent cardiothoracic surgery (e.g. coronary artery bypass graft surgery or aortic dissection
repair), there is often no time to wait for the drug to washout of the body. Currently, there are two approved reversal agents for DOACs.
reversal agent is recommended nor used in current clinical practice during cardiothoracic surgery due to a multitude of concerns that
(PhaseBio) is currently in Phase 3 development as a reversal agent for ticagrelor and recently reported single arm, non-randomized data
that showed pre-operative platelet inhibition reversal, but also occurrence of similar serious post-administration thrombotic events
as observed with the other DOAC reversal agents.
believe the large reduction in bleeding and excellent safety already demonstrated with real world use of our blood purification technology
under CE Mark approval in Europe will make intraoperative antithrombotic drug removal the preferred approach over preoperative drug reversal
in cardiac surgery. Furthermore, we anticipate that our device will represent a very attractive value proposition for cardiac surgery
centers as a "one-stop shop" for managing patients on multiple antithrombotic drugs. Finally, the randomized, double-blind,
controlled U.S. STAR-T and STAR-D pivotal studies are designed to provide definitive clinical and health economic data and set the gold
standard for supportive evidence that none of our competitors have.
we believe the STAR-T and STAR-D studies are the fastest, highest visibility, and lowest risk path to potential U.S. FDA marketing approval
of DrugSorb-ATR to remove antithrombotic agents during cardiothoracic surgery. If successful, we believe this approval will be a core
driver of substantial growth for our company.
our Clinical Priorities
the importance of the STAR-T and STAR-D trials to our overall strategy, we have decided to streamline our clinical activities to ensure
the focus of our financial and personnel resources to execute upon these two lead programs and to prepare for potential U.S. commercialization.
Because of this, we have made the difficult, but appropriate decision to voluntarily end the 400-patient multicenter U.S. REFRESH 2-AKI
pivotal study, which remains blinded. Importantly, there were no safety issues in the REFRESH 2-AKI trial. This decision was made strictly
for business reasons to ensure focus on the vital U.S. STAR-T and STAR-D clinical programs. We have also taken into account the costs
of the remaining portion of the REFRESH 2-AKI trial, the expected timing of completing the trial, delays caused by COVID, the evolution
of the change and perceived importance of acute kidney injury after cardiothoracic surgery, and the expensive and lengthy path to PMA
(pre-market approval) approval in the absence of Breakthrough Device Designation for this application. We believe the antithrombotic
removal program is superior to the REFRESH 2-AKI application in all of these aspects. This decision is expected to save in excess
of $5 million over the planned duration of REFRESH 2-AKI. Over the years, we have learned a lot from this program, including generation
of high quality good clinical practice (GCP) - level randomized, controlled data supporting the safety of CytoSorb use during cardiothoracic
surgery that we have already reported to the FDA for STAR-T and STAR-D, while also demonstrating the ability of CytoSorb to reduce both
plasma free hemoglobin and activated complement, two important clinical targets. We plan to work with our CRO to close out the trial,
unblind the study, and do a full analysis of the data in order to glean additional insights.
addition, we have decided to end the single arm CYTATION trial, a pharmacodynamic study on ticagrelor removal during cardiothoracic surgery
in Germany. The U.S. STAR-T randomized, controlled trial is a superior design and makes CYTATION redundant. We will redirect those resources
to our active pipeline of important ongoing studies like the German PROCYSS and Hep-on-Fire trials, as well as execution of new clinical
studies when the STAR-T and STAR-D trials near completion.
remain confident in CytoSorbents' potential
summary, despite the depressed share price, we firmly believe this is the most exciting time in the Company's history given the
potentially game-changing opportunities that lie ahead. COVID has led to some bumps in the road without question and has decreased our
forecasting ability in the short-term. But we have made tremendous progress and created significant value, and now sit on the verge of
multiple potential catalysts.
results demonstrate that our core business is stable with the potential for rapid growth addressing substantial markets and unmet medical
of us at the Company have recently purchased shares of CytoSorbents in the open market at higher prices than where we sit today, including
myself (20,000 shares), Kathleen Bloch, our Chief Financial Officer (4,000 shares), and many non-reporting employees, because of our
conviction of the strength of our business.
thanks to all of you who have supported and invested in CytoSorbents and who continue to share our vision of the future as a highly successful
leader in treating serious life-threatening conditions with blood purification. We wish all of you a happy, healthy, and prosperous 2022!
Dr. Phillip Chan, MD, PhD
CytoSorbents Corporation (NASDAQ: CTSO)
Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.
Its flagship product, CytoSorb , is approved in the European Union with distribution in more than 70 countries around the world
as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome"
seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions
where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and
after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ